|
14 May 2020 |
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
|
|
13 May 2020 |
First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
|
|
13 May 2020 |
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
|
|
13 May 2020 |
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
|
|
13 May 2020 |
Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
|
|
13 May 2020 |
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement
|
|
13 May 2020 |
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
|
|
13 May 2020 |
Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
|
|
13 May 2020 |
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
|
|
13 May 2020 |
Sunovion Discontinues Dasotraline Program
|
|
13 May 2020 |
Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL Therapy
|
|
13 May 2020 |
Alvotech announces positive top-line results for two comparative studies for AVT02, a proposed biosimilar to HUMIRA® (adalimumab)
|
|
13 May 2020 |
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies
|
|
12 May 2020 |
Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial
|
|
12 May 2020 |
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
|
|
12 May 2020 |
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
|
|
12 May 2020 |
GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis
|
|
12 May 2020 |
Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy
|
|
12 May 2020 |
Sarclisa (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma
|
|
12 May 2020 |
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
|
